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Pathology currently plays a central role in the interdisciplinary
management of breast cancer by establishing the diagnosis,
estimating untreated clinical outcome (prognosis), and
predicting responsiveness to specific types of therapy
(prediction). Establishing the diagnosis of invasive breast
cancer (IBC) is the first and most critical responsibility of
pathologists. It is primarily based on microscopic evaluation
of tissue samples, which most often begins with evaluation of
image-guided core biopsies obtained by radiologists. The
diagnosis of IBC initiates prompt therapy by other members
of the interdisciplinary team. Typically, this first involves
surgeons, who excise the tumor (lumpectomy or mastectomy)
as well as some (sentinel) or all of the lymph nodes in the
ipsilateral axilla. Surgery is usually followed by various types
of adjuvant therapy managed by radiation and medial
oncologists, as well as social/psychological support by
mental health professionals.
Pathologists also evaluate the excised tumor and lymph
nodes to determine other important prognostic and predictive
features, and the results are essential for deciding on
adjuvant therapies. These features include identification of
the histologic type of IBC. Five major types are currently
recognized [1,2]. Four are characterized by relatively unique/
uniform histologic features and favorable clinical outcomes,
and thus they are referred to as ‘special’ histologic types
[1,3,4]. Collectively, the special types account for about 25%
of all IBCs, and include the so-called invasive lobular, tubular,
mucinous, and medullary carcinomas (approximately 15%,
5%, 3%, and 2%, respectively). The remaining 75% of IBCs
are histologically and prognostically very heterogeneous, and
they are referred to as ‘no-special-type’ carcinomas or, more
commonly, as ‘ductal’ carcinomas, which is a more historical
term [1,2]. Although the prognosis of ductal carcinomas is
generally worse than that of the special types (with the
exception of lobular carcinomas), this varies across a wide
continuum from very good to very poor.
Pathologists use histologic grading systems to estimate the
prognosis of ductal carcinomas, although grading is some-
times also applied to special types, but the information is less
useful in this setting. There are many systems for histologic
grading. Nearly all of them assess the degree of architectural
differentiation (tubule/acinus formation), nuclear atypia, and
growth (mitotic) rate in tumors, assigning points to each
category to obtain a total score. The sum scores are then
combined into two or three grades that are directly related to
prognosis. The Elston-Ellis modified Scarff-Bloom-Richardson
method, which categorizes tumors into low (3 to 5 points),
intermediate (6 or 7 points), and high (8 or 9 points) grades,
is currently the preferred method because it is relatively
simple, reproducible, and has the ability to identify tumors
with significantly different prognosis [5-7].
Other important prognostic features determined by patholo-
gists include tumor size, the status of surgical margins, and
axillary lymph nodes. Like histologic grade, tumor size is
related to prognosis in a direct and highly significant manner
[1,8]. It is usually determined by directly measuring the size of
the excised mass with a ruler, although small tumors are more
accurately measured microscopically in a tissue section on a
glass slide. The distance of tumor from the margin of surgical
excision is also important because it is inversely related to the
likelihood of local recurrence, especially in tumors removed by
lumpectomy [9]. Wide margins can be adequately measured
with a ruler, whereas close margins require microscopic
measurement. The presence of metastatic tumor deposits in
axillary lymph nodes is a highly unfavorable prognostic feature,
as are a high number of involved nodes and (to a lesser
degree) large size of the deposits, which are all determined
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microscopically [8]. Tumor size (T) and nodal status (N) are so
powerful prognostically that they comprise two of the three
features used in the TNM (where M means distant
metastases) breast cancer staging to convey the extent of
disease [10], which plays a major role in determining therapy.
The histopathologic evaluation of IBCs by pathologists has a
long and impressive history, and it is likely to remain important
for the foreseeable future because it provides so much
clinically useful information in a fast and inexpensive manner.
However, it also has substantial limitations, including an
inability to determine the molecular alterations within tumors
that, in addition to stage, are the major reasons for differ-
ences in prognosis and response to therapy. These
limitations have prompted an enormous amount of research
to identify and characterize important molecular features.
Estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor (HER)2 status are
three important molecular features of IBCs that have been
identified during the past 30 years, and their evaluation by
pathologists is now mandatory. ER and PR are growth-
regulating nuclear transcription factors that are usually
measured by immunohistochemistry (IHC), and the amount of
protein expressed is directly related to responsiveness to
endocrine therapy, which is why they are so important
[11,12]. HER2 is a growth factor receptor (among other
functions) at the cytoplasmic membrane. The level of
membrane protein is highly associated with amplification of
this oncogene, and thus HER2 status can be measured either
at the protein level by IHC or at the DNA level by assessing
gene copy number with assays such as fluorescence in situ
hybridization [13]. Over-expressed and/or amplified HER2 is
a relatively weak prognostic factor in untreated patients, but it
is a strong predictive factor for responsiveness to targeted
therapies such as trastuzumab [14,15], which is the primary
reason for measuring it. However, despite their usefulness,
ER, PR, and HER2 are still unable to predict response
accurately in many patients, which has motivated additional
research to find more powerful factors.
Recent studies, based primarily on newer high-throughput
technologies, have demonstrated that IBCs are enormously
diverse at the molecular level, which suggests that the
assessment of multiple molecular features simultaneously
may have more prognostic and predictive power than conven-
tional features. The ultimate goal is ‘personalized medicine’,
based on identifying the key molecular defects in each
patient’s tumor, permitting the use of safe and effective
therapies targeted at the specific defects in each patient.
During the past several years, many molecular signatures
have been identified by pathologists and other investigators.
The first important signature, reported in 2000, identified the
so-called intrinsic subtypes of breast cancer (luminal, basal,
and HER2) [16,17]. It was based on cDNA microarray
analysis of several hundred genes, which was later distilled to
IHC analysis of five to ten corresponding proteins by IHC
[18,19]. MammaPrint® (Agendia, Huntington Beach, CA,
USA) came soon thereafter (2002); it assesses the expres-
sion of 70 genes by microarray analysis to identify good and
poor risk breast cancers [20,21]. OncotypeDX® (Genomic
Health, Inc., Redwood City, CA, USA) followed (2004), which
measures 21 genes by quantitative PCR, resulting in a con-
tinuous recurrence score that is subdivided into low, inter-
mediate, and high risk groups [22]. Then came the Genomic
Grade Index (2006), which evaluates 96 genes using
microarrays [23], and the Molecular Grade Index (2007),
which appears to be as powerful prognostically as the
Genomic Grade Index but relies on only five genes, evaluated
using quantitative PCR [24]. These are the most notable
signatures, but there are many others.
All of these molecular signatures have provided fascinating
new insights into cancer biology, and they have more prog-
nostic and predictive power than conventional factors, but
surprisingly they are only incrementally more powerful, and
we are still far from realizing the dream of truly personalized
medicine. For example, in seminal validation studies of
OncotypeDX® [22,25] and MammaPrint® [20,21,26], some
conventional prognostic factors (for example, histologic grade
and tumor size) remained independently significant in
multivariate analyses predicting clinical outcome. Thus,
combining conventional factors with molecular signatures
appears to provide the most useful information. Despite all of
the effort invested in measuring multiple gene products, most
molecular signatures are reduced to two or three risk
categories (for instance, low, intermediate, and high), which
seems somewhat counterproductive. They are currently being
used primarily to optimize standard endocrine and cytotoxic
therapies, although a few ongoing clinical trials are also using
them to identify patients who may not need adjuvant
chemotherapy at all, which would be a major contribution
[27-29]. It is clearly still early in the game.
A recent meta-analysis of 13 major microarray studies com-
paring breast cancers (n = 553) with normal breast tissue
(n = 79) identified significant differences in the expression of
1,350 genes, but 90% were identified in only one study [30].
On average, the remaining 138 genes were identified in only
two studies, and the highest level of confirmation involved
upregulation of a single gene (GATA3) in only 6 of the 13
studies. It will be important to understand why there is such
poor agreement regarding specific molecular alterations
between studies and why molecular signatures provide only
modest improvements over conventional prognostic and
predictive factors. There are probably many contributing
factors, including differences in the quality and design of
studies, differences in the technology used and, perhaps
most importantly, the existence of truly enormous molecular
diversity between and within breast cancers.
Initial results from studies sequencing the genome of human
breast cancers suggest that an average tumor contains 20Page 3 of 4
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individual mutated genes [31], which translates to about 1089
possible combinations if all of the mutations are random or
stochastic, and if all 30,000 genes in our genome are cancer
genes. This far exceeds the number of stars in the visible
universe (estimated at 1021) [32], and is undoubtedly a
colossal overestimate, but it does foretell that the magnitude
of molecular diversity in breast cancer may be unexpectedly
large. Even if there are only 100 cancer-causing genes and
three mutations per tumor (and there is compelling evidence
that these are realistic or even low estimates), then there are
still 106 possible combinations of molecular defects in an
average human breast cancer. This is still an impossibly large
number to identify and design effective treatments against, so -
although we must continue to strive for improvement - our
expectations should be realistic and molecular signatures
may never be perfect.
A recent poll of breast cancer experts from around the world
identified the top priorities for future translational research in
breast cancer [33]. The top 10 were essentially all directed at
improving therapy in patients with breast cancer. Given the
apparently enormous molecular complexity of breast cancer,
and the corresponding enormous difficulties in treating it,
perhaps prevention should also be high on the list, especially
because it may be more achievable. It would certainly be
preferable.
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